Lacomed

Lacosamide, the active ingredient in Lacomed, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces the frequency and severity of focal seizures. - Epilepsy (adjunct therapy): provides additional seizure control when other agents are insufficient. - Refractory focal epilepsy: offers an alternative option for patients not responding to standard treatments.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Headache: occasional tension‑type headache. - Fatigue: feeling of tiredness or reduced energy. - Diplopia: temporary double vision. - Tremor: mild shaking of hands or limbs.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: emergence of thoughts of self‑harm. - Acute pancreatitis: inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or liver injury.

Patients should be aware of specific safety considerations when using Lacomed. - Cardiac monitoring: obtain baseline ECG and monitor PR interval during therapy. - Renal impairment: adjust dosing in patients with reduced kidney function. - Hepatic impairment: use caution and consider dose adjustment in liver disease. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Pregnancy and lactation: discuss potential risks with a healthcare professional before use. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lacosamide can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - CYP2C19 inhibitors (e.g., fluconazole, omeprazole): may increase lacosamide plasma levels. - Cardiac conduction agents (e.g., digoxin, quinidine): can exacerbate PR‑interval prolongation.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., carbamazepine, phenytoin): may alter seizure control. - CNS depressants (e.g., benzodiazepines, opioids): increase risk of sedation. - Alcohol: may potentiate dizziness and drowsiness. - Diuretics (e.g., furosemide): monitor electrolytes and renal function.